gletvax 6 injektionsvæske, suspension
europharma.dk aps - clostridium perfringens type b og c, beta toxoid, clostridium perfringens type d, epsilon toxoid, escherichia coli, antigen 987p (f6), escherichia coli, antigen k88ab (f4ab), escherichia coli, antigen k88ac (f4ac), escherichia coli, antigen k99 (f5) - injektionsvæske, suspension - svin
mycobac hyo vet. min 1,0 elisa enh/ml injektionsvæske, suspension
salfarm danmark a/s - mycoplasma hyopneumoniae, stamme atcc 25095, antigen (inaktiveret) - injektionsvæske, suspension - min 1,0 elisa enh/ml - svin
mycobac uno vet. min. 1,0 elisa un/ml injektionsvæske, suspension
salfarm danmark a/s - mycoplasma hyopneumoniae, stamme atcc 25095, antigen (inaktiveret) - injektionsvæske, suspension - min. 1,0 elisa un/ml - svin
bovilis rotavec corona vet. injektionsvæske, emulsion
intervet international b.v. - bovin coronavirus, stamme mebus (inaktiveret), bovin rotavirus, stamme uk-compton, serotype g6 p5, inaktiveret, escherichia coli, antigen k99 (f5) - injektionsvæske, emulsion - kvæg
nobivac leufel
virbac s.a. - oprenset rp-45 felv-kuvert antigen - inaktiverede viral vacciner - katte - aktiv immunisering af katte fra otte ugers alderen mod felin leukæmi til forebyggelse af vedvarende viraemia og kliniske tegn på den relaterede sygdomme.
flucelvax tetra
seqirus netherlands b.v. - a/darwin/6/2021(h3n2)-like strain (a/darwin/11/2021, wild type) / a/wisconsin/67/2022 (h1n1)pdm09-like strain (a/georgia/12/2022 cvr-167) / b/austria/1359417/2021-like strain (b/singapore/wuh4618/2021) / b/phuket/3073/2013-like virus (b/singapore/inftt-16-0610/2016, wild type) - influenza, human - influenza, inaktiveret, split virus eller overflade antigen - prophylaxis of influenza in adults and children from 2 years of age. flucelvax tetra bør anvendes i overensstemmelse med officielle anbefalinger.
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfom, mantelcelle - antineoplastiske midler - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).
vaxneuvance
merck sharp & dohme b.v. - pneumococcal polysaccharide conjugate vaccine (adsorbed) - pneumokokinfektioner - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. se afsnit 4. 4 og 5. 1 for information om beskyttelse mod specifikke pneumokokserotyper. the use of vaxneuvance should be in accordance with official recommendations.
ticovac junior 1,2 mikrog./0,25 ml injektionsv?ske, suspension, fyldt injektionsspr?jte
2care4 aps - tick-borne encephalitis virus antigen (neudoerfl stamme), inaktiveret - injektionsvæske, suspension, fyldt injektionssprøjte - 1,2 mikrog./0,25 ml
locametz
novartis europharm limited - gozetotide - radionuklidbilleddannelse - diagnostiske radioaktive lægemidler - dette lægemiddel er kun til diagnostisk brug. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.